An Open-Label Study of Cranial Electrotherapy Stimulation on Behavioral Regulation in a Mixed Neurodevelopmental Clinical Cohort

被引:1
|
作者
Brandes-Aitken, Annie [1 ,2 ]
Gerdes, Molly [1 ]
Hattangadi, Neil [1 ]
Shapiro, Kevin A. [1 ,3 ]
Marco, Elysa J. [1 ]
机构
[1] Cortica Healthcare Inc, San Diego, CA 92111 USA
[2] New York Univ, Dept Appl Psychol, New York, NY 10012 USA
[3] Childrens Hosp Los Angeles, Neurol Inst, Los Angeles, CA 90027 USA
关键词
cranial electrotherapy stimulation; neurodevelopment; sensory sensitivity; anxiety; emotion regulation; NONINVASIVE BRAIN-STIMULATION; ELECTRICAL-STIMULATION; EMOTION REGULATION; ADAPTIVE-BEHAVIOR; AUTISM; ANXIETY; CHILDREN; EFFICACY; INTERVENTION; METAANALYSIS;
D O I
10.31083/j.jin2205119
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: Individuals with neurodevelopmental disorders often report disturbances in the autonomic nervous system (ANS)-related behavioral regulation, such as sensory sensitivity, anxiety, and emotion dysregulation. Cranial electrotherapy stimulation (CES) is a method of non-invasive neuromodulation presumed to modify behavioral regulation abilities via ANS modulation. Here we examined the feasibility and preliminary effects of a 4-week CES intervention on behavioral regulation in a mixed neurodevelopmental cohort of children, adolescents, and young adults. Methods: In this single-arm open-label study, 263 individuals aged 4-24 who were receiving clinical care were recruited. Participants received at-home CES treatment using an Alpha-Stim (R) AID CES device for 20 minutes per day, 5-7 days per week, for four weeks. Before and after the intervention, a parent-report assessment of sensory sensitivities, emotion dysregulation, and anxiety was administered. Adherence, side effects, and tolerance of the CES device were also evaluated at follow-up. Results: Results showed a 75% completion rate, an average tolerance score of 68.2 (out of 100), and an average perceived satisfaction score of 58.8 (out of 100). Additionally, a comparison between pre- and post-CES treatment effects showed a significant reduction in sensory sensitivity, anxiety, and emotion dysregulation in participants following CES treatment. Conclusions: Results provide justification for future randomized control trials using CES in children and adolescents with behavioral dysregulation. Significance: CES may be a useful therapeutic tool for alleviating behavioral dysregulation symptoms in children and adolescents with neurodevelopmental differences.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Long-Term Effect of HCV Eradication in Patients With Mixed Cryoglobulinemia: A Prospective, Controlled, Open-Label, Cohort Study
    Gragnani, Laura
    Fognani, Elisa
    Piluso, Alessia
    Boldrini, Barbara
    Urraro, Teresa
    Fabbrizzi, Alessio
    Stasi, Cristina
    Ranieri, Jessica
    Monti, Monica
    Arena, Umberto
    Iannacone, Claudio
    Laffi, Giacomo
    Zignego, Anna Linda
    HEPATOLOGY, 2015, 61 (04) : 1145 - 1153
  • [22] Effectiveness of Levetiracetam in the Treatment of Lumbar Radiculopathy: An Open-Label Prospective Cohort Study
    Hamza, Maged S.
    Anderson, David Greg
    Snyder, John W.
    Deschner, Steven
    Cifu, David X.
    PM&R, 2009, 1 (04) : 335 - 339
  • [23] Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice
    Osorio-Gomez, Guiovana Fernanda
    Ortiz-Alvarez, Juan
    Diaz-Ceca, Delia
    Guijarro-Sanchez, Cesar
    Sanchez, Julian Conejo-Mir
    Crehuet, Pablo Fernandez
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (03) : 254 - 259
  • [24] An open-label study of fluvoxamine in outpatients with mixed anxiety-depressive disorder
    Houck, C
    Stankovic, S
    PSYCHOPHARMACOLOGY BULLETIN, 1997, 33 (03) : 530 - 530
  • [25] Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias:: An open-label, multicenter study
    Aguilar-Salinas, CA
    Fanghänel-Salmón, G
    Meza, E
    Montes, J
    Gulías-Herrero, A
    Sánchez, L
    Monterrubio-Flores, EA
    González-Valdez, H
    Pérez, FJG
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (06): : 729 - 733
  • [26] Gabapentin Improves Symptoms of Functional Dyspepsia in a Retrospective, Open-label Cohort Study
    Staller, Kyle
    Thurler, Andrea H.
    Reynolds, Justin S.
    Dimisko, Laurie R.
    McGovern, Ryan
    Skarbinski, Kristina F.
    Kuo, Braden
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (05) : 379 - 384
  • [27] Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study
    Berkovich, Regina R.
    Sokolov, Alexey Y.
    Togasaki, Daniel M.
    Yakupova, Aida A.
    Cesar, Paul-Henry
    Sahai-Srivastava, Soma
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 64 - 69
  • [28] Open-label study of hemin for acute porphyria: Clinical practice implications
    Anderson, Karl E.
    Collins, Stephen
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 (09): : 801.e19 - 801.e24
  • [29] Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: An open-label study
    Spivak, B
    Mozes, T
    Mester, R
    Kodelik, M
    Weizman, A
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2001, 11 (03) : 279 - 284
  • [30] High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort study
    Liang, Qian
    Li, Nan
    Song, Shurong
    Zhang, Aihua
    Li, Ni
    Duan, Ying
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2016, 42 (10) : 1354 - 1360